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INTRODUCTION
T his JPGN supplement contains the papers presented at the 8thmeeting on ‘‘Probiotics, Prebiotics and New Foods’’ which is
held every two years in Rome since 1999. The Rome meeting was
probably the first meeting that fully focused on functional nutrition
and encompassed gastroenterologists, nutritionists, microbiolo-
gists, immunologists and pediatricians together with representatives
from companies as well as consumers and members of regulatory
bodies. Since its first edition, the meeting structure includes the
‘‘Pediatric Day’’ which is endorsed by ESPGHAN. The Pediatric
Day is a highly qualified forum in which the various aspects of
childhood functional nutrition are discussed by experts from all
over the world and consistently shows how advanced is the pediatric
world in the field of functional nutrition using probiotics, probiotics
and new foods.
In the former editions, the meeting focused on the definitions
of functional foods and the options to best investigate their effects in
children. It became clear that the approach to functional nutrients
was similar to that used for drugs. However, an interesting differ-
ence between drugs and nutrients was that the sequence of exper-
imental phases with the classical sequence from in vitro to animal
and finally to human clinical studies was not as strict with foods as it
was with drugs. The opposite approach starting from clinical effects
and then trying to understand their mechanisms through basic
science was discussed in the earlier editions of the Rome meetings,
raising the concept of ‘‘reverse translational research’’ applied to
functional foods. Basic science however is broad and includes
various approaches. Molecular microbiological methods led to
the vision of intestinal microbiota as a major target of nutritional
interventions. The idea of looking at single bacterial species to
explain clinical observations was completely changed with the
concept of dysbiosis which alludes to a global de-structure of
intestinal microbiota involved in the pathogenesis of many chronic
conditions in childhood. It also became evident that several chronic
diseases have a ‘‘microbial signature’’, consisting in a specific
change of intestinal microbiota. A similar pattern of de-structure
could therefore be counteracted with a nutritional intervention with
probiotics to restructure the intestinal microbiota.
It also became clear that in most diseases the structural-
functional relationships between intestinal microbiota and clinical
conditions is different from children and adults. For example
selected probiotics are effective in adult but not in children with
inflammatory bowel diseases. Also the pattern of effects in intes-
tinal functional disorders is different in adults and children.
Therefore it is clear that age is a major determinant of
intestinal microbiota and hence the success and failure of using
pre- or probiotics shows an age-related pattern.
During the subsequent editions of the Rome meeting scien-
tists met consumers and members of regulatory bodies from Europe
as well as from North America to discuss definitions and rules in
what was progressively becoming a major area of research with
important consequences in human health. An entire edition of the
meeting focused on definitions and the importance of health claims
obtained with nutritional interventions. The issue was delicate as it
had major implications in terms of consumers health as well as
marketing. The importance to properly define an ‘‘effect on health’’
by a functional nutrient was discussed jointly by scientists and
members of regulatory bodies. The European Food Safety
Authority (EFSA) is in charge of reviewing claims proposed by
companies and this had a major effect in driving the development of
functional nutrition in recent years. The concept of obtaining solid
scientific evidence to support a specific claim to be then presented
to consumers was a major feature in driving research in nutrition.
The importance of this approach was to shift more financial
resources of companies from advertisement to science. Before
advertising a (putative) claim, this had to be supported by scientific
proofs. This translated in an advantage for consumers because what
they were paying for had indeed an added value in terms of health.
However, there was often a gap between industry and
regulatory bodies and the ‘‘dossiers’’ that were presented for
scrutiny to health authorities sometimes did not comply with what
was asked. This gap was a barrier against the implementation of a
fruitfull collaboration between science and industry. As a matter of
fact, investment into scientific research by companies did not fully
translated into an advantage in terms of market. A guidance
recently released by EFSA may be effective in fill the gap (1).
This guidance is intended to assist applicants in preparing appli-
cations for the authorisation of health claims related to the immune
system, the gastrointestinal tract and defence against pathogenic
microorganisms.
In the most recent edition of the Rome meeting, the discus-
sion focused on the combined evaluation of clinical and basic
science data and how the scientific evidence translated into guide-
lines. Metanalysis of RCTs on probiotics provide the material for
guidelines. It became clear that well conducted RCTs were the basis
for authoritative guidelines. This evolution in the world of probio-
tics was again functional to their successful development for
prevention and therapy, and led to an even closer similarity between
nutrients and drugs. In order to provide reliable indications on the
use of nutrients there was a need for critical evaluation of data and
metanalysis of RCTs. This pattern translated in an active role by
scientific societies that started to release evidence-based recom-
mendations on the use of probiotics for clinical purpose. The first
guideline containing reference to the use of probiotics was the
ESPGHAN/ESPID guideline for acute gastroenteritis (2). Today
both in Europe and in the USA, probiotic use for clinical purpose is
(critically) endorsed by guidelines (3–5), and this now applies to
several guidelines on gastroenteritis at world level (6). The code of
conduct adopted by scientific societies such as ESPGHAN provided
further credibility to the authoritative role of societal papers,
including position papers and guidelines. Papers presented at the
last edition of Rome meeting provide a broad view of the most
recent results obtained with probiotics in NASH and obesity, food
allergy and functional intestinal disorders.
It is interesting to observe that probiotics are now included or
proposed in virtually all areas of human and particularly childhood-
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health. In selected cases- as in acute gastroenteritis- the supporting
evidence is very strong and the clinical effects are compelling. In
other areas, the effects are less evident and difficult to investigate.
This is the case of obesity in which the effects may occur several
years after the administration of probiotics and often are the result
of many variables. In other conditions such as in functional
intestinal disorders, the results are loaded with substantial placebo
effect. Definitions and outcome parameters are also a limit in this
study and the Comment initiative has been active to solve those
issues (7).
Finally there are conditions in which the use -or non use of
probiotics may have very serious consequences as in the case of
necrotising enterocolitis in preterm babies. In the latter, adminis-
tration of probiotics has shown an effect on the most clearcut
clinical outcome: survival rate! So we go from a simple and
consistent evidence of clinical efficacy such as in gastroenteritis
to life saving indication in selected condition. The mechanisms of
the observed effects are also a target for research, as summarized in
this issue of JPGN.
The reader may find an interesting balanced and well based
overview on probiotics in this collection of papers from the 8th
Rome meeting on ‘‘Probiotics, Prebiotics and New Foods’’.
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